Trials / Terminated
TerminatedNCT00124839
Naltrexone in Borderline Personality Disorder
Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Central Institute of Mental Health, Mannheim · Academic / Other
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate whether naltrexone reduces the intensity and duration of flashbacks and dissociative states in patients with borderline personality disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Naltrexone | Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2007-10-01
- Completion
- 2008-03-01
- First posted
- 2005-07-28
- Last updated
- 2008-04-15
Locations
5 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00124839. Inclusion in this directory is not an endorsement.